Universe Pharmaceuticals INC
UPC
$4.20
$0.4010.53%
NASDAQ
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -6.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -6.92% | |||
| Cost of Revenue | 0.00% | -1.45% | |||
| Gross Profit | 0.00% | -19.53% | |||
| SG&A Expenses | 0.00% | -3.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.00% | -123.95% | |||
| Total Operating Expenses | 0.00% | -16.51% | |||
| Operating Income | 0.00% | 52.66% | |||
| Income Before Tax | 0.00% | -202.69% | |||
| Income Tax Expenses | 0.00% | -50.33% | |||
| Earnings from Continuing Operations | 0.00% | -140.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | -140.50% | |||
| EBIT | 0.00% | 52.66% | |||
| EBITDA | 0.00% | 56.46% | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||